Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FHD-286 + decitabine
- Development stage
- Unknown
- Lead developer
- Foghorn Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**FHD-286 + decitabine** is a combination investigational regimen currently in phase 1 clinical development for the treatment of relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)[1][3][7]. FHD-286 is a highly potent, selective, allosteric, orally available small-molecule inhibitor of BRG1 (SMARCA4) and BRM (SMARCA2), the mutually exclusive ATPase subunits of the SWI/SNF (BAF) chromatin remodeling complex[1][4]. Decitabine is a nucleoside analog and DNA methyltransferase inhibitor, used to induce hypomethylation and promote cell differentiation. FHD-286 acts by inhibiting BRG1 and BRM, resulting in myeloid differentiation and reduction of leukemic blasts[2][4][5]. Combining FHD-286 with decitabine aims to potentiate antileukemic effects and reduce risk of differentiation syndrome through cytoreduction[1][5]. This regimen is being developed by Foghorn Therapeutics for difficult-to-treat AML and MDS, especially in patients with adverse genetic factors or after multiple lines of therapy.
- Other names
- FHD-286 + decitabine
02
Targets
SMARCA4 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4)DNMT (DNA methyltransferase)SMARCA2 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily A member 2)
Beyond the preview
Go deeper on FHD-286 + decitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FHD-286 + decitabine.